Novo Nordisk shrugs off supply issues with record sales

The Danish pharma group reported sales growth of 33% in the first nine months of the year to DKK 166.4 billion ($23.7 billion), driven by a 58% rise in sales of once-weekly diabetes injection Ozempic (semaglutide) to DKK 65.7 billion.